GNI Group Ltd.
Disclosure of Remarks at Gyre Therapeutics Investor Meeting
Gyre anticipates revenue generation of approximately JPY 63.2 to 94.8 billion over five years from the hepatic fibrosis treatment F351, with ETUARY®, the pulmonary fibrosis treatment, expected to maintain revenue of around JPY 15.8 billion. Net profit margin is projected at 20–25%.
Key Figures
- Revenue Forecast in Hepatic Fibrosis Treatment Area: Approximately JPY 63.2 to 94.8 billion (5 years)
- Revenue Forecast for Pulmonary Fibrosis Treatment ETUARY®: Approximately JPY 15.8 billion (Maintenance expected)
- Net Profit Margin for Commercialized Products: 20% to 25%
AI要約
Business Outlook of Gyre Therapeutics
Gyre Therapeutics indicates the potential to generate revenue of approximately $400 to $600 million (approximately JPY 63.2 to 94.8 billion) over the next five years with its hepatic fibrosis treatment F351. The pulmonary fibrosis treatment ETUARY® is expected to maintain a revenue level of about $100 million (approximately JPY 15.8 billion) assuming no generic competition. Commercialized products are projected to achieve a net profit margin of 20% to 25%, with assumptions of tax incentives at research and development bases in Beijing and Shanghai.
Product Development Progress and Market Expansion Potential
Following approval for chronic hepatitis B/ fibrosis, F351 is expected to see off-label use for MASH and market expansion in rheumatic disease areas. Approximately 30–40% of pulmonary fibrosis-related revenue originates from rheumatic diseases, and Gyre expects to maintain and expand this revenue composition ratio. Cullgen’s TRK degrader CG001419 has confirmed safety and is in Phase II clinical trials, offering advantages in overcoming side effects of existing analgesics. The DAC complex demonstrates 10 to 100 times stronger efficacy compared to conventional drugs, with about half of research and development resources dedicated to advancing its development.
